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Editorial overview:  Where are we with treating musculoskeletal disorders? 
Isabel R Orriss & Vicky E MacRae 
There are numerous pathological conditions that affect the musculoskeletal system and connective 
tissues; these range from common bone disorders typically associated with ageing (e.g. osteoporosis) 
through to rare inherited calcification diseases (e.g.  pseudoxanthoma elasticum).  Many of these 
conditions lead to disability and represent a significant financial burden to healthcare systems, an issue 
that will only worsen with the increasingly ageing population.  Understanding the molecular mechanisms 
leading to the etiology of these disorders is essential for identifying and developing an effective 
treatment.  In many cases, study of rare diseases has provided important insights into the complex 
biological processes which underpin normal musculoskeletal function. This special issue contains 
articles which expertly review our current knowledge on the causes of and therapeutic options available 
to treat conditions including cancer in bone [1,2], osteoporosis [2,3], osteoarthritis [4], connective tissue 
calcifying diseases [5,6] and bone pain [7].  Recent developments in our understanding of osteocyte 
biology [8] and the interactions between fat and bone [9], which may yield novel therapeutic targets in 
the future, are also reviewed. 
The treatment of postmenopausal osteoporosis represents one of the success stories within the 
musculoskeletal field with several therapies being available.   Most of these treatments (e.g. 
bisphosphonates, Denosumab) act by inhibiting osteoclast activity and reducing bone resorption, 
thereby increasing bone mineral density.  At present the only bone anabolic agent currently available is 
the human parathyroid hormone (PTH) analogue teriparatide, which is not suitable for all patients.  The 
bisphosphonates have recently come under scrutiny because they reportedly prevent bone remodelling 
leading to atypical femoral fractures. Given these potential limitations, the past few years have seen a 
considerable drive to identify new treatments to prevent bone loss, in particular bone anabolic agents.  
The review by Harsløf and Langdahl summarises these recent developments discussing a number of 
promising therapeutic agents including odanacatib (a cathepsin K inhibitor), Romosozumab (a 
monoclonal antibody against sclerostin) and abaloparatide (a PTHrP fragment) [3].  The option of 
combination therapy (i.e. an anti-resorptive along with a bone anabolic) as a therapeutic approach is 
also considered.     
In stark contrast to osteoporosis, osteoarthritis currently lacks effective treatment. This degenerative 
joint disease is the most common form of arthritis and is characterised by loss of articular cartilage, 
subchondral bone thickening and osteophyte formation. Despite recent advances in knowledge, the 
underpinning molecular mechanisms are not fully understood.  At present clinical management is largely 
palliative and with an aging population there is an ever growing need for treatments which prevent the 
onset and progression of this condition. The review by Poulet and Staines elegantly discusses the 
different tissues of the joint which have been targeted for therapeutic intervention with a particular focus 
on the subchondral bone and synovial membrane [4].   They also examine how it is becoming 
increasingly evident that osteoarthritis is a complex, multi-factorial disease and so any one treatment 
may not be appropriate for all patients.  With the considerable amount of work taking place in this field, 
it is certainly one to watch for promising new developments. 
Despite recent advances, cancer still remains a major cause of mortality.   Bone can be affected by 
primary cancers (e.g. osteosarcoma) or, more commonly, the metastases associated with other 
tumours such as breast or prostate cancer.   Availability and efficacy of treatments vary depending on 
the cancer involved but generally bone metastases are considered incurable.  Consequently, there is a 
considerable amount of work being performed to identify new therapeutic targets for cancers in bone. 
This issue contains an elegant review by Gooding and Edwards focussing on multiple myeloma, which 
is a cancer of the plasma cells in the bone marrow [1].  In multiple myeloma, the cancer cells hijack the 
local microenvironment and disrupt bone homeostasis leading to significant bone loss. It is a relatively 
uncommon form of cancer but like secondary bone cancers there is currently no cure. The review also 
discusses some of the new avenues being explored in multiple myeloma research [1]; in particular it 
focuses on the interactions between the tumour cells and bone marrow niche and how this can be 
manipulated to treat multiple myeloma.   
Autophagy is an essential process which involves the degradation and reuse of intracellular structures 
and macromolecules.  Whilst specific regulators of autophagy are emerging as drugs or supplements 
for anti-cancer therapy, the effects of these compounds on the skeleton has yet to be elucidated. In this 
issue, Chagin [2] discusses the mTOR-autophagy pathway in relationship to epiphyseal chondrocytes, 
articular chondrocytes, osteoblasts, osteocytes and osteoclasts. Furthermore, the potential negative 
side effects of targeting either the mTOR pathway through anti-cancer treatment on bone growth and 
development are also highlighted.  
Skeletal conditions are a common cause of chronic pain which can have a significant impact on quality 
of life.  Bone pain is prevalent in a range of disorders including osteoporotic fractures, Paget’s disease, 
osteoarthritis and bone metastasis. At present, there are very few therapies which can attenuate bone 
pain without unwanted side effects and, thus, there is a significant need for novel treatments.  The past 
decade has seen an increase in the level of research into bone pain and as such the underlying 
mechanisms are beginning to emerge. Frost et al examine the latest developments in this field and 
discuss some of the exciting preclinical findings which could represent promising therapeutic targets 
(such as nerve growth factor) for treating bone pain [7].   
It is widely accepted that bone homeostasis involves complex interactions between osteoblasts, 
osteoclasts and osteocytes.  The importance of these interactions is considered in a number of the 
reviews in this special issue [4,6,8].  Osteocytes are increasingly being viewed as essential regulators 
of bone remodelling.  The review by Prideaux et al summarises current knowledge regarding the role 
of osteocytes in bone formation, bone resorption and perilacunar remodelling [8].  It also discusses the 
opportunities for therapeutics which specifically target osteocytes or osteocyte-derived factors (such as 
the anti-sclerostin antibody, romosozumab).    
More recently, it has become apparent that bone cells also interact with other cell types and 
understanding these complex signalling pathways may help to identify novel pathways which can be 
exploited therapeutically.  Bone remodelling is a highly active and regulated process that maintains 
skeletal structural integrity. This vital function is characterised by alternating phases of destruction by 
osteoclasts and formation by osteoblasts, and has a high energetic cost. To sustain energy balance, 
excess consumed calories are stored as glycogen, triglycerides and protein, allowing the body to 
continue to function in states of starvation and increased energy expenditure. Adipose tissue provides 
the largest natural store of excess calories as triglycerides and plays an important role as an endocrine 
organ in energy homeostasis and beyond.  Suchacki, et al. explore the novel role of bone marrow 
adipose tissue (MAT) as an endocrine organ and discuss the pharmacological agents that regulate 
MAT [9].   
Whilst regulated mineralisation is essential for the normal functioning of the skeleton, soft tissue 
calcification usually results in severe pathological changes.  There are many diseases which are 
characterised by abnormal calcium deposition in connective tissues.   Some of these are widespread 
and the consequence of chronic disorders; for example vascular calcification is a common consequence 
of type 2 diabetes and chronic kidney disease.  Others are rare inherited genetic diseases such as 
pseudoxanthoma elasticum (PXE) and generalised arterial calcification in infancy (GACI). At present 
there are only very limited pharmaceutical strategies to prevent or regress these disorders. The review 
by Rashdan et al discusses the molecular mechanisms underpinning these conditions and potential 
targets that could be used for therapeutic intervention [5].  It further highlights how the study of these 
rare disorders has yielded important information about the processes regulating biomineralisation.  
Pyrophosphate, a simple and ubiquitous molecule, prevents unwanted calcification and acts as the 
body’s natural “water softener”.  Since its role in inhibiting mineralisation was discovered in the 1960s, 
the importance of pyrophosphate within the body has tended to be overlooked. This issue contains a 
detailed review by Orriss et al highlighting the fundamental role of pyrophosphate in regulating bone 
mineralisation and preventing soft tissue calcification [6].  From a pharmacological perspective it is 
important to remember that the discovery of pyrophosphate paved the way for the development of the 
bisphosphonates.  These drugs, which are chemically stable analogues of pyrophosphate, are an 
effective treatment for a range of conditions including osteoporosis and metastatic bone disease. New 
uses for bisphosphonates continue to be suggested; for example, as a treatment for conditions 
associated with unwanted calcification such as vascular calcification. 
Taken together, the reviews in this special issue highlight the considerable pharmacological advances 
that there have been within the musculoskeletal field in the last 40 years.  Whilst treatments for some 
conditions, such as osteoporosis, have been particularly successful, a vast number of diseases affecting 
the musculoskeletal system remain without effective treatment.  Our increased understanding of the 
cellular and molecular mechanisms underpinning these conditions has identified a number of promising 
therapeutic targets.  However, further work is still required to determine whether these pre-clinical 
findings can translate to effective treatments for these musculoskeletal and connective tissue diseases.  
This is particularly important given that many of these disorders are associated with ageing and, 
globally, the population is increasingly getting older. 
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